arrow
P

P. Sevelda

hietzing hospital
H指数:35
被引数:6,279

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Zoledronic acid to prevent rebound fractures after stopping adjuvant denosumab: a randomized controlled sub-study of the ABCSG-18 trial
2024-05-020
PRE
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

绝经后乳腺癌芳香化酶抑制剂辅助治疗的持续时间

2021-07-2991
OA
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
2021-03-248
OAAI
Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
2020-09-015
OAAI
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
2020-06-0132
PREAI
The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial
2016-02-1522
PRE
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
LANCET
IF88.5
2015-08-01403
PREAI
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

唑来膦酸联合他莫昔芬辅助内分泌治疗与阿那曲唑加卵巢功能抑制治疗绝经前早期乳腺癌: 奥地利乳腺癌和结直肠癌研究组试验12的最终分析

2015-02-01232
OAAI
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
2011-09-14548
OAAI
ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy
BREAST
IF7.9
2009-03-010
OAAI
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy
2008-04-0134
PREAI